First multi-whole-genome study of IBD in African Americans

February 19, 2021

In African Americans, the genetic risk landscape for inflammatory bowel disease (IBD) is very different from that of people with European ancestry, according to results of the first whole-genome study of IBD in African Americans. The authors say that future clinical research on IBD needs to take ancestry into account.

Findings of the multi-center study, which analyzed the whole genomes of more than 1,700 affected individuals with Crohn's disease and ulcerative colitis and more than 1,600 controls, were published on February 17 in the American Journal of Human Genetics.

As part of their analysis, the researchers developed an algorithm that corrects for ancestry when calculating an IBD polygenic risk score. Polygenic risk scores are tools for calculating gene-based risk for a disease, which are used for IBD as well as other complex conditions such as coronary artery disease.

"Even though the disease destination looks the same, the populations look very different, in terms of what specific genes contribute to risk for IBD," says lead author Subra Kugathasan, MD. "It shows that you can't develop a polygenic risk score based on one population and apply it to another."

Kugathasan is scientific director of the pediatric IBD program and director of the Children's Center for Transplantation and Immune-mediated Disorders at Children's Healthcare of Atlanta, as well as Marcus professor of pediatrics and human genetics at Emory University School of Medicine.

The first author of the paper is geneticist Hari Somineni, PhD, who earned his doctorate working with Kugathasan at Emory, and is now working at Goldfinch Bio in Massachusetts.

The primary sites to recruit study participants were Emory, Cedars-Sinai and Rutgers, along with Johns Hopkins and Washington University at Saint Louis. Along with Kugathasan, the co-senior authors and co-organizers of the study were Steven Brant, MD from Rutgers and Dermot McGovern, MD, PhD from Cedars-Sinai.

"One of our goals in treating IBD is to move toward a more personalized approach," says McGovern, the Joshua L. and Lisa Z. Greer Chair in Inflammatory Bowel Disease Genetics at Cedars-Sinai. "Deciphering the genetic architecture is an important part of this effort. Studies such as this one are vital to ensure that diverse populations, including African-Americans, benefit from the tremendous advances promised by genomic medicine."

Having a first-degree relative with a form of IBD confers a greater risk than any known environmental factor. African-Americans are conventionally thought to be less at risk for IBD, but Kugathasan says that view may reflect disparities in diagnosis and access to healthcare.

The study showed that the most important genetic risk locus for IBD in African Americans -- PTGER4 - is relatively minor in European ancestry populations, Kugathasan says. In contrast, two gene loci that are major in Europeans - NOD2 and IL23R - play smaller roles in African Americans.

There is some overlap in genetic risk factors based on the African-American population historically having about 20 percent European genetic background, with known IBD risk factors such as IL23R coming from the European side.

In 2016, the research team published the first genome-wide association study of IBD in African Americans, identifying regions of the genome associated with ulcerative colitis only in people of African descent.

Future clinical studies of IBD treatments need to take the genetic background of specific populations into account, Kugathasan says. Several therapies are being developed for IBD targeting the IL23 receptor pathway, partly because IL23R is a major genetic risk factor, with little focus on PTGER4. That needs to change, he says.

The current study also identified rare genetic variants conferring IBD risk that are specific to African Americans, which had not been observed in previous studies. The variants are connected to the gene encoding calbindin 2 (CALB2), a protein involved in nervous system signaling.

What the study did not find - disappointing the researchers - were a host of rare genetic variants that explain the "missing heritability" in IBD among African-Americans. In genome-wide association studies, missing heritability refers to disease risk that is not accounted for by common gene variants.

For the future of the IBD field, Kugathasan says studies of gene-environment interactions - examining factors such as diet, microbiome, or toxic exposures -- may yield insights that genome-wide association studies have not.
-end-
This research was supported by grants from the National Institute of Diabetes and Digestive and Kidney Diseases (DK062431, DK087694, DK062413, DK046763, DK062429, DK062422 DK062420, DK062432 and DK062423), along with the National Institute of Allergy and Infectious Diseases (AI067068), the National Institute of Dental and Craniofacial Research (U54DE023789) and the Rutgers Crohns and Colitis Center of New Jersey.

Emory Health Sciences

Related Inflammatory Bowel Disease Articles from Brightsurf:

People with inflammatory bowel disease still die earlier despite increase in life
A study comparing life expectancy of people with inflammatory bowel disease (IBD) and without found that, while life expectancy increased for both groups, people with IBD generally died sooner.

Cell therapy designed to treat inflammatory bowel disease
The UPV/EHU's NanoBioCel research group has for many years been developing systems enabling cells to be used as drugs.

Team develops wearable sensor to help people with inflammatory bowel disease
University of Texas at Dallas researchers have designed a wearable device that monitors sweat for biomarkers that could signal flare-ups of inflammatory bowel disease (IBD).

Antibiotics associated with increased risk of inflammatory bowel disease
Antibiotics use, particularly antibiotics with greater spectrum of microbial coverage, may be associated with an increased risk of new-onset inflammatory bowel disease (IBD) and its subtypes ulcerative colitis and Crohn's disease.

Yes, inflammatory bowel disease and celiac disease are linked
A systematic review and meta-analysis that has determined there is a nine-fold increased risk of having IBD for patients with a previous diagnosis of celiac disease.

The effects of inflammatory bowel disease on pregnancy
Inflammatory bowel disease (IBD) -- including Crohn's disease and ulcerative colitis -- often affects women of childbearing age.

5 major advances in inflammatory bowel disease (IBD) treatment
Summary of five impactful studies to be presented at the Crohn's & Colitis Congress, a partnership of the Crohn's & Colitis Foundation and the American Gastroenterological Association (AGA).

Researchers identify a possible cause and treatment for inflammatory bowel disease
In a study published online in PNAS on Jan. 20, 2020, Prof.

Does inflammatory bowel disease carry certain risks during pregnancy?
Pregnant women with inflammatory bowel disease (IBD) are more likely to undergo delivery by Caesarean section and face certain risks during pregnancy, according to an analysis published in Alimentary Pharmacology & Therapeutics.

Inhibiting a protease could improve the treatment of inflammatory bowel disease
Scientists at the CNIC and CSIC have identified a function of a protease that could be the future target of drugs to treat inflammatory bowel disease.

Read More: Inflammatory Bowel Disease News and Inflammatory Bowel Disease Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.